右美托咪定在急性病成人无创通气中的安全性与疗效:随机试验的系统评价与Meta分析
结果显示右美托咪定降低插管风险、谵妄风险和ICU住院时长,但增加心动过缓和低血压风险。
要点
- 右美托咪定可降低NIV患者插管风险(RR 0.54)和谵妄风险(RR 0.34)。
- 右美托咪定增加心动过缓(RR 2.80)和低血压(RR 1.98)风险,需监测。
- 证据确定性多为中等,部分结果受不精确性限制,需更大样本RCT验证。
核心结论
- 与任何镇静策略或安慰剂相比,右美托咪定降低谵妄风险和机械通气需求,但增加心动过缓和低血压风险。
主要发现
- 右美托咪定降低插管风险(RR 0.54;95%CI 0.41-0.71;中等确定性)。
- 右美托咪定降低谵妄风险(RR 0.34;95%CI 0.22-0.54;中等确定性)。
- 右美托咪定缩短ICU住院时长(MD -2.40天;95%CI -3.51至-1.29天;低确定性)。
- 右美托咪定增加心动过缓风险(RR 2.80;95%CI 1.92-4.07;中等确定性)。
- 右美托咪定增加低血压风险(RR 1.98;95%CI 1.32-2.98;中等确定性)。
临床怎么用
- 对ICU内急性呼吸衰竭接受NIV的成人,可考虑右美托咪定以改善耐受性并降低插管和谵妄风险。
- 使用右美托咪定时应监测心动过缓和低血压。
局限性
- 结果受不精确性限制,需进一步开展大型RCT验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although clinical studies have evaluated dexmedetomidine as a strategy to improve noninvasive ventilation (NIV) comfort and tolerance in patients with acute respiratory failure (ARF), their results have not been summarized. RESEARCH QUESTION: Does dexmedetomidine, when compared with another sedative or placebo, reduce the risk of delirium, mortality, need for intubation and mechanical ventilation, or ICU length of stay (LOS) in adults with ARF initiated on NIV in the ICU? STUDY DESIGN AND METHODS: We electronically searched MEDLINE, EMBASE, and the Cochrane Library from inception through July 31, 2020, for randomized clinical trials (RCTs). We calculated pooled relative risks (RRs) for dichotomous outcomes and mean differences (MDs) for continuous outcomes with the corresponding 95% CIs using a random-effect model. RESULTS: Twelve RCTs were included in our final analysis (n = 738 patients). The use of dexmedetomidine, compared with other sedation strategies or placebo, reduced the risk of intubation (RR, 0.54; 95% CI, 0.41-0.71; moderate certainty), delirium (RR, 0.34; 95% CI, 0.22-0.54; moderate certainty), and ICU LOS (MD, -2.40 days; 95% CI, -3.51 to -1.29 days; low certainty). Use of dexmedetomidine was associated with an increased risk of bradycardia (RR, 2.80; 95% CI, 1.92-4.07; moderate certainty) and hypotension (RR, 1.98; 95% CI, 1.32-2.98; moderate certainty). INTERPRETATION: Compared with any sedation strategy or placebo, dexmedetomidine reduced the risk of delirium and the need for mechanical ventilation while increasing the risk of bradycardia and hypotension. The results are limited by imprecision, and further large RCTs are needed. TRIAL REGISTRY: PROSPERO; No.: 175086; URL: www.crd.york.ac.uk/prospero/.
引用
- Lewis K, Piticaru J, Chaudhuri D, et al. Safety and Efficacy of Dexmedetomidine in Acutely Ill Adults Requiring Noninvasive Ventilation: A Systematic Review and Meta-analysis of Randomized Trials. Chest. 2021. PMID: 33434496. doi:10.1016/j.chest.2020.12.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。